CLINICAL TRIALS PROFILE FOR ANISODAMINE
✉ Email this page to a colleague
Clinical Trials for Anisodamine
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT01929044 ↗ | Efficacy of Buscopan® in Comparison With 654-II (Anisodamine) in Acute Gastric or Intestinal Pain | Completed | Boehringer Ingelheim | Phase 3 | The aim of the study is to assess the efficacy of Buscopan® (hyoscine butylbromide) in comparison to 654-II (anisodamine)in acute gastric or intestinal spasm-like pain. |
NCT02279147 ↗ | Cholinergic Anti-inflammatory Pathway in Prevention & Treatment of the SIRS in Patients With Jaundice After Operation. | Unknown status | Wanqing Gu | Phase 1/Phase 2 | RATIONALE:Anticholinesterase drugs and cholinergic M receptor antagonist are applied to patients who have obstructive jaundice after operation. PURPOSE:This clinical trial was designed to lower the incidence and mortality of operation complications in patients with obstructive jaundice . |
NCT02442440 ↗ | Anisodamine Critically Ill SeptIc Shock | Completed | Jinhua Central Hospital | Phase 1/Phase 2 | Anisodamine has been widely used in China for its pharmacological effect on improving microcirculation during shock. It has been reported that anisodamine is effective in reducing mortality rate in children with meningitis. however, its effectiveness in patients with septic shock has not been systematically investigated. The aim of the study is to investigate the effectiveness of anisodamine in the treatment of patients with septic shock. |
NCT03299452 ↗ | Clinical Studies by Using Alphacait to Screen Drugs for Advanced Solid Tumor | Unknown status | Alphacait, LLC | Phase 2 | This is a single-center, open-label, single-arm, non-randomized study designed to evaluate PFS, safety, overall survival (OS), objective response rate (OPR), disease control rate (DCR) and biomarkers of cancer therapy based on Alphacait screening system in subjects with advanced malignant tumor. |
NCT03299452 ↗ | Clinical Studies by Using Alphacait to Screen Drugs for Advanced Solid Tumor | Unknown status | Haining Health-Coming Biotech Co., Ltd. | Phase 2 | This is a single-center, open-label, single-arm, non-randomized study designed to evaluate PFS, safety, overall survival (OS), objective response rate (OPR), disease control rate (DCR) and biomarkers of cancer therapy based on Alphacait screening system in subjects with advanced malignant tumor. |
NCT05634057 ↗ | Effectiveness of Anisodamine Hydrobromide Combined With Heparin for the Treatment of Critically Ill Patients With Septic Shock | Not yet recruiting | Chen Ying | N/A | The study aimed to investigate the effectiveness of anisodamine hydrobromide combined with heparin in the treatment of septic shock, in the hope that the therapy will provide alternatives to the treatment of septic shock. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Anisodamine
Condition Name
Clinical Trial Locations for Anisodamine
Clinical Trial Progress for Anisodamine
Clinical Trial Phase
Clinical Trial Sponsors for Anisodamine
Sponsor Name